GlassScriptPhysician profile
Aundria Hebert Cannon
NPI 1942663885
$4,669.11
in general payments reported to CMS, 2019-2025
30 companies · $922 in 2025
The $922 reported for 2025 was more than what 95% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $805 · 2022: $1,155 · 2023: $1,229 · 2024: $558 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.38 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $520.67 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $491.84 | 2021-2025 | Annovera |
| Exeltis, USA INC. | $478.18 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $373.29 | 2023-2025 | Myfembree |
| Abbvie INC. | $357.02 | 2021-2024 | |
| Pfizer INC. | $347.21 | 2021-2025 | |
| Evofem Biosciences, INC. | $206.76 | 2021-2025 | Phexxi, Solosec, Phexx |
| Myriad Women'S Health, INC. | $196.25 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $185.41 | 2021-2025 | |
| Avion Pharmaceuticals | $181.65 | 2021-2023 | Balcoltra |
| Myovant Sciences INC. | $178.60 | 2021-2022 | |
| Hologic Sales and Service, LLC | $135.50 | 2021-2024 | Aptima |
| Coopersurgical, INC. | $121.92 | 2021-2025 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $110.80 | 2021-2024 | Jada System |
| Therapeuticsmd, INC. | $106.28 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $98.14 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Scynexis, INC. | $85.74 | 2021-2022 | |
| Sage Therapeutics, LLC | $81.19 | 2022-2025 | Zurzuvae |
| Shield Therapeutics INC | $51.67 | 2024-2025 | |
| Biom'Up France Sas | $49.05 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $48.30 | 2023-2024 | Exparel |
| Merck Sharp & Dohme LLC | $45.27 | 2022-2023 | Gardasil 9 |
| Mylan Pharmaceuticals INC. | $37.74 | 2022 | |
| Davol INC. | $36.85 | 2022 | |
| Renovia INC | $32.04 | 2021 | |
| Medtronic, INC. | $29.79 | 2022-2023 | Ligasure |
| Dexcom, INC. | $28.23 | 2025 | Dexcom G6 Transmitter |
| Urovant Sciences INC | $24.53 | 2022 | |
| Lupin INC. | $15.40 | 2021 | |
| Currax Pharmaceuticals LLC | $13.79 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aundria Cannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.